According to a recent study, men who have inflammation in their prostate may have a lower risk of developing prostate cancer in the future. Researcher analyzed prostate tissue samples from 6,200 men between the ages of 50 and 75. All the tissue samples returned negative biopsies, indicating that the men were all cancer-free. However, at a follow-up biopsy two years later, 900 participants (approximately 14%) had prostate cancer. After analyzing the tissue samples, researchers found that men with signs of acute inflammation or chronic inflammation during the original biopsy were 25 or 35 percent less likely to be diagnosed with prostate cancer.
Two years later researchers determined that only acute inflammation in the original biopsy was associated with a lower prostate cancer risk. Even with these results, inflammations link to prostate cancer is still currently under debate. This study suggests that knowing the type and severity of information may help physicians decide how their patients should be followed-up with in the future. Dr. Moreira, a urologist, says that the severity of inflammation in prostate tissues should be reported with biopsy results, although currently not all labs do this.
Previous studies looking at the correlation between inflammation and prostate cancer have yield mixed results. In epidemiological studies, researchers linked some types of inflammation with having higher risk of prostate cancer. However, in other studies that examined the pathology of prostate, they found a lower risk of prostate cancer in people with inflammation. Dr. Moreira cites a possible “detection bias” from examining men who had symptoms of inflammation because they were more likely to see a physician. These men would likely undergo a cancer screening and have any cancer detected compared to men who didn’t have inflammation and hadn’t seen a physician. Although the exact correlation between inflammation and prostate cancer is unclear, it is possible that inflammation acts as an immune response when the body recognizes malignant cells as foreign agents and eliminates them before they can become cancerous or form a tumor.
If you or someone you know would like to participate in a clinical trial and would like to get connected to the right researcher, please visit us at Reg4All.